Discussing the Recently Approved Tonmya, a Centrally Acting Non- Opioid Analgesic for the Treatment of Fibromyalgia

• Key learnings from Phase III trials include study design, patient selection, endpoint development, and regulatory engagement to streamline approval
• Pharmacologically targeting non-refreshing sleep can improve pain and address other core symptoms of fibromyalgia
• Evaluating selectivity in pain drug development requires balancing toxicology risk with efficacy to maximize therapeutic potential

Speakers:

Gregory Sullivan

Chief Medical Officer

Tonix Pharmaceuticals